- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05913427
Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC) (PESETA)
Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC)
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Aldo Roccaro
- Phone Number: +390303996851
- Email: coordinamento.ricerca@asst-spedalicivili.it
Study Locations
-
-
-
Brescia, Italy, 25123
- Recruiting
- Alfredo Berruti
-
Contact:
- Alfredo Berruti
- Phone Number: +390303995260
- Email: alfredo.berruti@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of ACC
- Locally advanced or metastatic disease not amenable to radical surgery resection
- ECOG performance status 0-2
- Effective contraception
- Life expectancy > 3 months
- Age > 18 years
- Adequate bone marrow reserve (neutrophils >1,000/mm3 and/or platelets >80,000/mm3) and organ function (including renal, liver and cardiac function)
- Be able to comply with the protocol procedures and provide written informed consent.
Exclusion Criteria:
- History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in situ, or other treated malignancies where there has been no evidence of disease for at least 2 years
- Renal insufficiency (estimated glomerular filtration rate [GFR]<50 mL/min/1.73 m2) or significant liver insufficiency (serum bilirubin>2 times the upper normal range and/or serum alanine aminotransferase [ALT] or aspartate aminotransferase [AST]>3 times the upper normal range). GFRs will be calculated according to the validated formula (MDRD)
- Pregnancy or breast feeding
- Congestive heart failure (ejection fraction<45%)
- Preexisting grade 2 peripheral neuropathy
- Previous or current treatment with mitotane or other antineoplastic drugs for ACC
- Previous radiotherapy for ACC
- Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration or that, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EDP-M plus MEGESTROL ACETATE 160 mg
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.
Concomitant mitotane therapy will be administered continuously.
Megestrole 160 mg 2 tablets will be administered once daily (in the morning) and will be stopped 21 days after the last administration of the EDP.
|
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.).
Other Names:
|
Placebo Comparator: EDP-M plus PLACEBO
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.
Concomitant mitotane therapy will be administered continuously.
Placebo 2 tablets will be administered once daily (in the morning) and will be stopped 21 days after the last administration of the EDP.
|
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days.
Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the activity of the combination regimen (EDP-M plus progesterone (EDP-MP) versus EDP-M plus placebo) in advanced/ metastatic patients with ACC.
Time Frame: 18 months
|
Comparison of proportion of patients attaining an Objective Response (Objective Response Rate, ORR), evaluated by RECIST criteria between the 2 treatment arms.
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum cortisol from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum UFC from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum salivary cortisol from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in ACTH from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum 11-deoxycortisol from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum aldosterone from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum PRA from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum androstenedione from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum DHEA-S from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum progesterone from baseline in the two treatment arms;
|
18 months
|
Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;
Time Frame: 18 months
|
Changes in serum total testosterone from baseline in the two treatment arms;
|
18 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alfredo Berruti, ASST Spedali Civili di Brescia
Publications and helpful links
General Publications
- Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabarin A, Quinkler M, de la Fouchardiere C, Schlumberger M, Mantero F, Weismann D, Beuschlein F, Gelderblom H, Wilmink H, Sender M, Edgerly M, Kenn W, Fojo T, Muller HH, Skogseid B; FIRM-ACT Study Group. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7;366(23):2189-97. doi: 10.1056/NEJMoa1200966. Epub 2012 May 2.
- Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Nov;31(11):1476-1490. doi: 10.1016/j.annonc.2020.08.2099. Epub 2020 Aug 27. No abstract available. Erratum In: Ann Oncol. 2022 Dec 21;:
- Fiorentini C, Fragni M, Perego P, Vezzoli S, Bonini SA, Tortoreto M, Galli D, Claps M, Tiberio GA, Terzolo M, Missale C, Memo M, Procopio G, Zaffaroni N, Berruti A, Sigala S. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocortical Cancer: A Preclinical Study. J Clin Endocrinol Metab. 2016 Dec;101(12):4594-4602. doi: 10.1210/jc.2016-2414. Epub 2016 Sep 14.
- Fragni M, Fiorentini C, Rossini E, Fisogni S, Vezzoli S, Bonini SA, Dalmiglio C, Grisanti S, Tiberio GAM, Claps M, Cosentini D, Salvi V, Bosisio D, Terzolo M, Missale C, Facchetti F, Memo M, Berruti A, Sigala S. In vitro antitumor activity of progesterone in human adrenocortical carcinoma. Endocrine. 2019 Mar;63(3):592-601. doi: 10.1007/s12020-018-1795-x. Epub 2018 Oct 26.
- Rossini E, Tamburello M, Abate A, Beretta S, Fragni M, Cominelli M, Cosentini D, Hantel C, Bono F, Grisanti S, Poliani PL, Tiberio GAM, Memo M, Sigala S, Berruti A. Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer. Front Endocrinol (Lausanne). 2021 Apr 26;12:669426. doi: 10.3389/fendo.2021.669426. eCollection 2021.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Adrenal Gland Diseases
- Adrenal Cortex Neoplasms
- Adrenal Gland Neoplasms
- Adrenal Cortex Diseases
- Carcinoma
- Adrenocortical Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Central Nervous System Stimulants
- Appetite Stimulants
- Etoposide
- Etoposide phosphate
- Cisplatin
- Doxorubicin
- Liposomal doxorubicin
- Mitotane
- Megestrol
- Megestrol Acetate
Other Study ID Numbers
- ASSTBS-FARONCO- PESETA-20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adrenocortical Carcinoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Adrenocortical Carcinoma | Stage III Adrenocortical Carcinoma | Stage IV Adrenocortical CarcinomaUnited States
-
Dartmouth-Hitchcock Medical CenterM.D. Anderson Cancer Center; Dana-Farber Cancer Institute; AstraZeneca; Kentuckiana...CompletedNonresectable Adrenocortical CarcinomaUnited States
-
Latin American Cooperative Oncology GroupNot yet recruitingCarcinoma Adrenal | Carcinoma, Adrenocortical RecurrentBrazil
-
Memorial Sloan Kettering Cancer CenterRecruitingAdrenocortical Carcinoma | ACC | Metastatic Adrenocortical CarcinomaUnited States
-
Burzynski Research InstituteTerminatedStage IV Adrenocortical CarcinomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedAdrenocortical Carcinoma
-
National Cancer Institute (NCI)CompletedAdrenal Cortex NeoplasmsUnited States
-
National Cancer Institute (NCI)RecruitingNeuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinomas | Carcinoma, Adrenal Cortical | Carcinoma, AdrenocorticalUnited States
-
University Medical Center GroningenRadboud University Medical Center; Maastricht University Medical Center; UMC... and other collaboratorsRecruitingAdrenocortical Carcinoma | Adrenal IncidentalomaNetherlands
Clinical Trials on Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
-
Azienda Socio Sanitaria Territoriale degli Spedali...Unknown
-
Xiaojun ChenRecruitingOverweight | Fertility Issues | Obese | Endometrial CarcinomaChina
-
Cambridge University Hospitals NHS Foundation TrustAnticancer Fund, BelgiumCompleted
-
Xiaojun ChenRecruitingAtypical Endometrial Hyperplasia | Fertility Issues | Overweight and ObesityChina
-
Fudan UniversityPeking Union Medical College HospitalRecruitingEndometrial Neoplasm Malignant Stage IChina
-
Xiaojun ChenHuashan HospitalWithdrawnAtypical Endometrial Hyperplasia | Fertility Issues | Obese
-
Collaborative Group for Adrenocortical Carcinoma...National Cancer Institute (NCI); German Federal Ministry of Education and ResearchCompletedCarcinoma, Adrenal CorticalFrance, Austria, Netherlands, United States, Australia, Germany, Italy, Sweden
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)TerminatedEndometrial CancerUnited States, Canada
-
University of ArkansasTerminatedMultiple MyelomaUnited States
-
Merck Sharp & Dohme LLCRecruitingMetastatic Castration-Resistant Prostate CancerUnited States, Austria, Canada, France, Germany, Ireland, Italy, Mexico, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, Spain, Finland, Australia, Denmark